drugset / Trial / NCT04723563

Nebulized Heparin for the Treatment of COVID-19

NCT04723563

Phase 4 Completed 50 enrolled Frederick Health
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, placebo controlled study to determine if nebulized heparin may reduce the need for mechanical ventilation in hospitalized patients with the novel coronavirus, also known as COVID-19. This will be a part of a larger meta-trial.

Timeline

Start
2021-02-22
Primary completion
2021-08-23
Completion
2021-08-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Heparin Other / unclassified 25000 iu Other